Q/C Technologies (QCLS)
Developing silicon-photonic processors for AI inference alongside legacy drug candidates.
Something off on this page? Send us feedback.
Designs silicon-photonic processors intended for AI inference while retaining clinical-stage and preclinical drug candidates. The pre-revenue platform has disclosed no completed OPU, benchmark, customer, manufacturing partner, or commercial model for the current computing initiative.
Pursues a proprietary silicon-photonic optical processing unit for AI inference, aiming to develop chip architectures that use light for the matrix multiplications central to the workload. The computing program has no disclosed completed chip, benchmark, customer, manufacturing partner, or commercial launch date, and has generated no product revenue.
Retains isomyosamine, a clinical-stage oral small molecule for frailty, and Supera-CBD, a preclinical synthetic cannabidiol analog; both assets are under review for divestiture, licensing, or partnership.
Centers its physical footprint on a San Francisco headquarters and planned integrated-photonics laboratory. The computing initiative depends on internally developed intellectual property, functional validation, analog precision, nonlinear computation, memory integration, and eventual system integration.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.0M · Total debt $371.2K · Total assets $22.9M · Shareholders' equity $19.1M
- Revenue
- $0
- Operating income
- −$6.8M
- Net income
- −$6.6M
No dividends on record.
| Institutions17 holders · as of Mar 31, 2026 | 35.53% | 627.6K shares | |
| Insiders7 holders · as of May 14, 2026 | 37.58% | 663.7K shares | |
| Otherremainder | 26.89% | 474.9K shares |
1.77M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Chelsea Sierra VossInsiderdirector | 17.07% | 301,455 | Form 4filed May 14, 2026 ↗ |
Joshua SilvermanInsiderdirector, officer: Executive Chairman | 14.85% | 262,191 | Form 4filed Apr 15, 2026 ↗ |
Quinn Opportunity Partners LLCInstitution | 11.97% | 211,390 | 13Fas of Mar 31, 2026 |
Jane Street Group, LLCInstitution | 7.14% | 126,188 | 13Fas of Mar 31, 2026 |
UBS Group AGInstitution | 4.42% | 77,989 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 30, 2026 | Chelsea Sierra Voss | director | +1,753 | $3.15 |
| Sep 4, 2025 | PharmaCyte Biotech, Inc. | 10 percent owner | +889,865 | |
| Nov 14, 2025 | PharmaCyte Biotech, Inc. | 10 percent owner | +889,865 |
- Nvidia
Dominant electronic AI-inference alternative at data-center scale.
- AbbVie
Large-scale TNF-pathway alternative through Humira.
- Amgen
Established TNF-blocker alternative through Enbrel.
- Jazz Pharmaceuticals
Marketed cannabidiol epilepsy therapy versus a preclinical CBD analog.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Q/C Technologies | $1.95 | +2.09% | $3.4M | — | — | — | — |
| Nvidia | $224.67 | +0.11% | $5.44T | 28.4 | 18.7 | 17.9 | +105.9% |
| AbbVie | $261.54 | −0.06% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Amgen | $442.50 | −0.08% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Jazz Pharmaceuticals | $246.83 | +0.55% | $15.43B | 16.8 | 9.7 | 3.4 | +15.6% |
| Median | 27.9 | 18.0 | 6.7 | +12.9% |